Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy.

Kemp K, Morse R, Wexler S, Cox C, Mallam E, Hows J, Donaldson C

Center for Research in Biomedicine, Faculty of Applied Sciences, University of West of England, Bristol, UK. kevin.kemp@bristol.ac.uk

Hematopoietic recovery after high-dose chemotherapy (HDC) in the treatment of hematological diseases may be slow and/or incomplete. This is generally attributed to progressive hematopoietic stem cell failure, although defective hematopoiesis may be in part due to poor stromal function. Chemotherapy is known to damage mature bone marrow stromal cells in vitro, but the extent to which marrow mesenchymal stem cells (MSCs) are damaged by HDC in vivo is largely unknown. To address this question, the phenotype and functional properties of marrow MSCs derived from untreated and chemotherapeutically treated patients with hematological malignancy were compared. This study demonstrates a significant reduction in MSC expansion and MSC CD44 expression by MSCs derived from patients receiving HDC regimens, thus implicating potential disadvantages in the use of autologous MSCs in chemotherapeutically pretreated patients for future therapeutic strategies. The clinical importance of these HDC-induced defects we have observed could be determined through prospective randomized trials of the effects of MSC cotransplantation on hematopoietic recovery in the setting of HDC with and without hematopoietic stem cell rescue.

Published 21 May 2010 in Ann Hematol, 89(7): 701-13.
Full-text of this article is available online (may require subscription).

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.